Drug pricing has been the subject of Congressional inquiries, government investigations, and media attention. Generic drugs have long played an important role in reducing drug prices. Has the recent wave of generic drug company consolidation adversely affected pricing? Are overlap divestitures sufficient? Are prices being fixed, as might be suggested by DOJ’s criminal investigation and related civil litigation? Steven Tenn is a panelist on this topic.
For more information on this event, click here.
An economic interpretation of Rule 23(b)(3) for antitrust classes
In this article, CRA’s Sean Durkin explains the economic incentives behind class definitions in antitrust cases and why those incentives can lead to classes...